« Back
Home /
Repaglinide

Repaglinide

Item no.	CS-0979-100mg
Manufacturer	ChemScene
CASRN	135062-02-1
Amount	100mg
Category	Cardiovascular Research Ischemia & Reperfusion Injury Hypertension Reagents & Chemicals Arrhythmias Molecules
Type	Molecules
Specific against	other
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Similar products	135062-02-1
Available
Alternative Names	AG-EE 388 ZW; AG-EE 623ZW
CAS	135062-02-1
Purity	>98%
Formula	C27H36N2O4
MWt	452.59
Solubility	DMSO : >= 50 mg/mL (110.48 mM)
Clinical Information	Launched
Pathway	Others
Target	Others
Biological Activity	Repaglinide(AG-EE 623ZW) is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes. In Vitro: Repaglinide(AG-EE 623ZW) is very rapidly absorbed (tmax less than 1 hour) with a t1/2 of less than one hour. Furthermore, repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) was effective (P < 0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

CS-0979-100mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 100mg

available

Delivery expected until 9/4/2025

Compare

Add to wishlist

Get an offer

Request delivery time